Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Int J STD AIDS. 2012 Apr;23(4):235–241. doi: 10.1258/ijsa.2011.011189

Table 1.

HIV vaccine attribute profiles across three groups

HIV vaccine attributes Multiethnic Los Angeles group
(n = 143)
Los Angeles-Thai community group
(n = 27)
Aboriginal peoples-Toronto group (n = 13)
Efficacy 95% versus 50% 99% versus 50% 95% versus 50%
Cross-clade protection Multiple types versus one type Multiple types versus one type Multiple types versus one type
Side-effects None versus minor None versus minor None versus minor
Duration of protection Lifetime versus 10 years 10 years versus 1 year Lifetime versus 10 years
Numbers of doses 1 versus 3 1 versus 4 2 versus 5
Cost US$10 versus US$50 Free versus US$250 US$10 versus US$100
Route of administration Oral versus injection Oral versus injection
Vaccine-induced
    seropositivity
Test HIV+ for 3 months versus test HIV+
    for 2 years